Open an account

Liquidia

LQDA · NASDAQ

$36.35+$2.22 (+6.50%)TodayMarket closed ·
Prev close $34.13

About LQDA

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company is headquartered in Morrisville, North Carolina and currently employs 216 full-time employees. The company went IPO on 2018-07-26. The firm is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The firm operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.

Employees
216
Headquarters
Morrisville, North Carolina
Listed
Jul 26, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
liquidia.com

LQDA key statistics

Market cap
3.25B
Price-earnings ratio
24.55
Dividend yield
—
Average volume
6.77M
Volume
4.00M
Open price
$33.90
High today
$36.93
Low today
$33.65
52 Week high
$93.61
52 Week low
$21.94

Liquidia (LQDA) at a glance

As of Oct 20, 2026, Liquidia (LQDA) shares are priced at $36.35, giving the company a market cap of 3.25B and a price-to-earnings ratio of 24.55.

Today the stock has traded between $33.65 and $36.93. The current price is 8.0% above the day's low and 1.6% below its high.

Volume so far is 4.00M shares, below the average of 6.77M shares a day.

Over the past year Liquidia has ranged from $21.94 to $93.61, and now sits 20% of the way up that range.

Liquidia met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported $0.74 per share against an estimate of $0.7577.

The average analyst price target is $78.40, 115.7% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 9 analyst ratings say Buy
  • Buy66.7%
  • Hold22.2%
  • Sell11.1%
Price target · 10 analystsAvg $78.40
Low
$40.40
Now
$36.35
High
$136.50

LQDA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 45.3% on average.

  1. Q3 FY24: reported -$0.30 per share against an estimate of -$0.3808
  2. Q4 FY24: reported -$0.46 per share against an estimate of -$0.3819
  3. Q1 FY25: reported -$0.45 per share against an estimate of -$0.4055
  4. Q2 FY25: reported -$0.49 per share against an estimate of -$0.4397
  5. Q3 FY25: reported -$0.04 per share against an estimate of -$0.4094
  6. Q4 FY25: reported $0.17 per share against an estimate of $0.184
  7. Q1 FY26: reported $0.52 per share against an estimate of $0.4183
  8. Q2 FY26: reported $0.74 per share against an estimate of $0.7577

LQDA news

  • Avi Kapoor

    Nasdaq Dips Over 400 Points; Bank of America Shares Tumble After Q3 Results

  • Avi Kapoor

    Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday

  • Rishabh Mishra

    Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain Even as September Inflation Report Comes In Hotter Than Expected— ASML, AZZ, GME in Focus (UPDATED)

  • Neeraj Jain

    Liquidia Settles Bitter Fight With United Therapeutics

  • Press releaseBusiness Wire

    LIQUIDIA CORPORATION LQDA INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 57.2% Share Drop

  • Press releasePRNewswire

    Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky

  • Avi Kapoor

    First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday

  • Press releaseBusiness Wire

    LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law

Similar companies

Companies in the same industry as Liquidia

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.